secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apellis Pharmaceuticals, Inc. (APLS)
CIK:        0001492422
Form:       8-K
Filed at:   2026-03-02T23:59:59+00:00
Accession:  0001193125-26-084156
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Apellis adds Dr. Mikael Dolsten as independent Class I director
---------------------------------------------------------------

- Dr. Mikael Dolsten elected to Apellis Board as Class I director effective March 1, 2026, serving until the 2027 annual meeting.
- Dolsten deemed independent under Nasdaq rules; no committee appointments at this time.
- Received initial equity grant: option with $300,000 Black-Scholes value (3-year vest) and RSUs worth $300,000 (1-year cliff vest).
- Standard indemnification agreement in place; no family relationships or transactions with the Company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1492422/000119312526084156/0001193125-26-084156-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1492422/000119312526084156/d115780d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-084156

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer